Vigroux A, Bergon M, Zedde C
Laboratoire de Synthèse et Physicochimie Organique Associé au CNRS, Université Paul Sabatier, Toulouse, France.
J Med Chem. 1995 Sep 29;38(20):3983-94. doi: 10.1021/jm00020a012.
N-(Substituted 2-hydroxyphenyl)- and N-(substituted 2-hydroxypropyl)carbamates based on masked active benzoxazolones (model A) and oxazolidinones (model B), respectively, were synthesized and evaluated as potential drug delivery systems. A series of alkyl and aryl N-(5-chloro-2-hydroxyphenyl)carbamates 1 related to model A was prepared. These are open drugs of the skeletal muscle relaxant chlorzoxazone. The corresponding 4-acetamidophenyl ester named chlorzacetamol is a mutual prodrug of chlorzoxazone and acetaminophen. Chlorzacetamol and two other mutual prodrugs of active benzoxazolones and acetaminophen were obtained in a two-step process via condensation of 4-acetamidophenyl 1,2,2,2-tetrachloroethyl carbonate with the appropriate anilines. Based on model B, two mutual prodrugs of acetaminophen and active oxazolidinones (metaxalone and mephenoxalone) were similarly obtained using the appropriate amines. All the carbamate prodrugs prepared were found to release the parent drugs in aqueous (pH 6-11) and plasma (pH 7.4) media. The detailed mechanistic study of prodrugs 1 carried out in aqueous medium at 37 degrees C shows a change in the Brönsted-type relationship log t1/2 vs pKa of the leaving groups ROH: log t1/2 = 0.46pKa-3.55 for aryl and trihalogenoethyl esters and log t1/2 = 1.46pKa-16.03 for alkyl esters. This change is consistent with a cyclization mechanism involving a change in the rate-limiting step from formation of a cyclic tetrahedral intermediate (step k1) to departure of the leaving group ROH (step k2) when the leaving group ability decreases. This mechanism occurs for all the prodrugs related to model A. Regeneration of the parent drugs from mutual prodrugs related to model B takes place by means of a rate-limiting elimination-addition reaction (E1cB mechanism). This affords acetaminophen and the corresponding 2-hydroxypropyl isocyanate intermediates which cyclize at any pH to the corresponding oxazolidinone drugs. As opposed to model A, the rates of hydrolysis of mutual prodrugs of model B clearly exhibit a catalytic role of the plasma. It is concluded from the plasma studies that the carbamate substrates can be enzymatically transformed into potent electrophiles, i.e., isocyanates. In the case of the present study, the prodrugs are 2-hydroxycarbamates for which the propinquity of the hydroxyl residue and the isocyanate group enforces a cyclization reaction. This mechanistic particularity precludes their potential toxicity in terms of potent electrophiles capable of modifying critical macromolecules.
分别基于掩蔽的活性苯并恶唑酮(模型A)和恶唑烷酮(模型B)合成了N-(取代的2-羟基苯基)-和N-(取代的2-羟丙基)氨基甲酸酯,并将其作为潜在的药物递送系统进行了评估。制备了一系列与模型A相关的烷基和芳基N-(5-氯-2-羟基苯基)氨基甲酸酯1。这些是骨骼肌松弛剂氯唑沙宗的开环药物。相应的4-乙酰氨基苯基酯氯唑沙醇是氯唑沙宗和对乙酰氨基酚的共同前药。氯唑沙醇以及活性苯并恶唑酮和对乙酰氨基酚的另外两种共同前药是通过4-乙酰氨基苯基1,2,2,2-四氯乙基碳酸酯与适当的苯胺缩合,分两步得到的。基于模型B,使用适当的胺类似地得到了对乙酰氨基酚与活性恶唑烷酮(美他沙酮和甲酚恶酮)的两种共同前药。发现制备的所有氨基甲酸酯前药在水性(pH 6 - 11)和血浆(pH 7.4)介质中均能释放出母体药物。在37℃的水性介质中对前药1进行的详细机理研究表明,离去基团ROH的布仑斯惕型关系log t1/2对pKa发生了变化:对于芳基和三卤代乙基酯,log t1/2 = 0.46pKa - 3.55;对于烷基酯,log t1/2 = 1.46pKa - 16.03。当离去基团能力降低时,这种变化与一种环化机理一致,该机理涉及限速步骤从环状四面体中间体的形成(步骤k1)转变为离去基团ROH的离去(步骤k2)。这种机理适用于所有与模型A相关的前药。与模型B相关的共同前药中母体药物的再生通过限速消除 - 加成反应(E1cB机理)进行。这产生了对乙酰氨基酚和相应的2-羟丙基异氰酸酯中间体,它们在任何pH下都会环化生成相应的恶唑烷酮药物。与模型A不同,模型B的共同前药的水解速率明显显示出血浆的催化作用。从血浆研究得出的结论是,氨基甲酸酯底物可以被酶转化为强效亲电试剂,即异氰酸酯。在本研究的情况下,前药是2-羟基氨基甲酸酯,其中羟基残基和异氰酸酯基团的接近性促使发生环化反应。这种机理特殊性排除了它们作为能够修饰关键大分子的强效亲电试剂的潜在毒性。